Women taking compounded bioidentical hormones for symptoms of menopause don't know as much as they should about the therapy.
Recent survey results suggest women may be taking compounded bioidentical hormones to treat menopause without understanding the risks and unknowns of the therapy.
To gain a better understanding of compounded hormone therapy, researchers conducted two online surveys aimed at reaching women 40 years and older. These unregulated compounded hormones are widely used to ease the symptoms of menopause.
- Women using compounded hormones to alleviate menopause symptoms appear to not understand the difference between their drugs and FDA-approved medications.
- Patients should be warned that any compounded medication they take may not necessarily contain the substances in the amounts prescribed.
The survey results, which reached about 800 through Harris Interactive Inc. and more than 2,000 with Rose Research LLC, were used to calculate a projection that as many as 1 million to 2.5 million women are using compounded hormone therapy.
Many women, however, didn’t understand that these compounded drugs are not FDA approved and are instead formulated by pharmacies.
"These results indicate a general lack of understanding about key differences between compounded and FDA-approved hormone therapy. This publication establishes the need for better education on this topic," said Margery Gass, MD, executive director of The North American Menopause Society, in a news release highlighting the survey results.
The study authors concluded that providers have an opportunity to better educate women who are considering hormone therapy, and especially in explaining the differences between how FDA-approved therapies and compounded drugs are monitored.
The study, which was funded by Therapeutics MD, was published online in Menopause, the journal of The North American Menopause Society.
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
Study links premature menopause to musculoskeletal pain and sarcopenia risks
May 1st 2024A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.
Read More